TrIEM

TrIEM:

Leading products ICM-53 is in the early preclinical stage. ICM-53 could effectively control tumor growth with low toxicity in rodent studies. Combination with other immune checkpoint blockers further improved anti-tumor efficacy with low toxicity. IND-enabling studies of ICM-53 has been in progress.

ICM-53
  • B7H3+ tumor targeted long-acting IL-15 superagonist
  • Selectively stimulates proliferation of NK cells and CD8+ T cells in tumor
  • Balanced activities of B7H3 binding and IL15
  • Improved therapeutic index due to decreasing systemic IL15 exposure
  • High production yield in stable CHO expression system
  • High homogeneity and stability
  • Aiming a safe dose similar to that of aB7H3 mAb, much higher than competitor’s IL15-based immuno-cytokines
  • More opportunities for drug combination strategies
  • Broad market prospects: a wide range of indications of B7H3+ malignancy
ICM-061
  • Effectively activate tumor-infiltrating lymphocytes (TILs) within the immunosuppressive tumor microenvironment
  • Mimic the natural trans-presentation mechanism, significantly improving pharmacokinetic properties, extending drug half-life, and reducing dosing frequency.
  • Effectively reduces immune-related adverse reactions and minimizes systemic side effects of IL-15

Patients resistant to PD-1/PD-L1 inhibitors may benefit from the potent immune-activating effects of this therapeutic approach.

Scroll to Top